Hologic, Inc. revised earnings guidance for the Fiscal year 2024. For the year, the Company expects revenues of $4,000 million to $4,050 million compared to previous guidance of $3,990 million to $4,065 million and GAAP EPS of $3.45 to $3.55 compared to previous guidance of $3.52 to $3.67.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.8 USD | -0.26% | -1.63% | +3.29% |
May. 22 | FDA classifies recall of Hologic's implant as 'most serious' | RE |
May. 22 | FDA classifies recall of Hologic's implants for soft tissue as 'most serious' | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.29% | 17.22B | |
+10.03% | 223B | |
+13.59% | 195B | |
+20.01% | 144B | |
+30.83% | 111B | |
+2.05% | 65.01B | |
+15.38% | 53.02B | |
+3.96% | 50.45B | |
+8.37% | 44.15B | |
+3.27% | 36.45B |
- Stock Market
- Equities
- HOLX Stock
- News Hologic, Inc.
- Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024